Assetmark, Inc Seagen Inc. Transaction History

Assetmark, Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	BUY	$191.51 - $216.16 $272,327 - $307,379	1,422 Added 16.59%	9,995 $2.12 Million
Q2 2023 Aug 11, 2023	SELL	$187.64 - $206.25 $72,053 - $79,200	-384 Reduced 4.29%	8,573 $1.65 Million
Q1 2023 May 05, 2023	BUY	$127.59 - $203.08 $93,523 - $148,857	733 Added 8.91%	8,957 $1.81 Million
Q4 2022 Feb 10, 2023	BUY	$117.37 - $139.17 $41,314 - $48,987	352 Added 4.47%	8,224 $1.06 Million
Q3 2022 Nov 01, 2022	BUY	$135.27 - $180.11 $202,634 - $269,804	1,498 Added 23.5%	7,872 $1.08 Million
Q2 2022 Aug 03, 2022	BUY	$108.81 - $179.33 $151,354 - $249,448	1,391 Added 27.91%	6,374 $1.13 Million
Q1 2022 May 13, 2022	BUY	$119.61 - $157.85 $305,005 - $402,517	2,550 Added 104.81%	4,983 $718,000
Q4 2021 Feb 14, 2022	BUY	$142.57 - $190.86 $298,256 - $399,279	2,092 Added 613.49%	2,433 $376,000
Q3 2021 Nov 12, 2021	BUY	$142.45 - $169.82 $21,794 - $25,982	153 Added 81.38%	341 $58,000
Q1 2021 May 14, 2021	BUY	$137.51 - $190.8 $25,851 - $35,870	188 New	188 $26,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

Stay updated on Assetmark, Inc with notifications on news.